-
公开(公告)号：US20190008768A1
公开(公告)日：2019-01-10
申请号：US16131777
申请日：2018-09-14
Applicant: Biogen MA Inc.
Inventor： Peter Zawaneh , Shyam B. Karki , Michael Kaufman , Cheuk-Yui Leung , Jinquan Dong , Ernest Quan , Kalyan Vasudevan
Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.
-
公开(公告)号：US11033509B2
公开(公告)日：2021-06-15
申请号：US16076849
申请日：2017-02-08
Applicant: BIOGEN MA INC.
Inventor： Shyam B. Karki , Peter Zawaneh , Cheuk-Yui Leung , Kalyan Vasudevan , Yiqing Lin , Jin Xu , Andrea Trementozzi , Ivan Nestorov
Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
-
公开(公告)号：US20180153845A1
公开(公告)日：2018-06-07
申请号：US15527531
申请日：2015-11-19
Applicant: BIOGEN MA INC.
Inventor： Shyam B. Karki , Peter Zawaneh , Cheuk-Yui Leung , Kalyan Vasudevan , Yiqing Lin , Jin Xu , Andrea Trementozzi
CPC classification number: A61K31/225 , A61K9/1676 , A61K9/209 , A61K9/2826 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2873 , A61K9/288 , A61K9/2886 , A61K9/5078 , A61P25/00 , A61P37/00
Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
-
公开(公告)号：US11820760B2
公开(公告)日：2023-11-21
申请号：US17283301
申请日：2019-10-15
Applicant: BIOGEN MA INC.
Inventor： Fengmei Zheng , Anton Peterson , Kalyan Vasudevan , Chaomin Li , Daniel B. Patience , Yiqing Lin
IPC: C07D405/14
CPC classification number: C07D405/14 , C07B2200/13
Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.
-
公开(公告)号：US20220098150A1
公开(公告)日：2022-03-31
申请号：US17322382
申请日：2021-05-17
Applicant: Biogen MA Inc.
Inventor： Nishanth Gopinathan , Erwin Irdam , William Kiesman , Daw-long A. Kwok , Yiqing Lin , Frederick Osei-Yeboah , Matthew Peterson , Kenny Tran , Kalyan Vasudevan
IPC: C07D207/16
Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[2-fluorophenyl)methyl]oxy}phenyl-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.
-
Patent Agency Ranking
公开(公告)号：US20190046456A1
公开(公告)日：2019-02-14
申请号：US16076849
申请日：2017-02-08
Applicant: BIOGEN MA INC.
Inventor： Shyam B. Karki , Peter Zawaneh , Cheuk-Yui Leung , Kalyan Vasudevan , Yiqing Lin , Jin Xu , Andrea Trementozzi , Ivan Nestorov
IPC: A61K9/50 , A61K31/225 , A61K9/48
Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
-
7.发明申请Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate 审中-公开每日管理二甲基富马酸盐的控释剂型公开(公告)号：US20160310419A1
公开(公告)日：2016-10-27
申请号：US15102306
申请日：2014-12-12
Applicant: BIOGEN MA INC.
Inventor： Peter Zawaneh , Shyam B. Karki , Michael Kaufman , Cheuk-Yui Leung , Jinquan Dong , Ernest Quan , Kalyan Vasudevan
CPC classification number: A61K9/0065 , A61K9/0004 , A61K9/14 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2086 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2886 , A61K9/4808 , A61K9/5026 , A61K9/5031 , A61K9/5042 , A61K9/5047 , A61K9/5073 , A61K31/22
Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.
Abstract translation: 含有富马酸单甲酯，可以在体内代谢为富马酸单甲酯的化合物或其药学上可接受的盐或其组合的控释剂型，其中富马酸单甲酯，可在体内代谢成富马酸甲酯的化合物或 其药学上可接受的盐或其组合被递送至受试者。 还提供了通过口服施用含有富马酸单甲酯，可以在体内代谢成富马酸甲酯的化合物或其药学上可接受的盐或其组合来治疗疾病或病症（例如多发性硬化症）的方法 其中富马酸单甲酯，可在体内代谢成富马酸单甲酯的化合物或其药学上可接受的盐或其组合。
-
公开(公告)号：US11197842B2
公开(公告)日：2021-12-14
申请号：US15527531
申请日：2015-11-19
Applicant: BIOGEN MA INC.
Inventor： Shyam B. Karki , Peter Zawaneh , Cheuk-Yui Leung , Kalyan Vasudevan , Yiqing Lin , Jin Xu , Andrea Trementozzi
Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
-
公开(公告)号：US20210369629A1
公开(公告)日：2021-12-02
申请号：US17319694
申请日：2021-05-13
Applicant: BIOGEN MA INC.
Inventor： Shyam B. Karki , Peter Zawaneh , Cheuk-Yui Leung , Kalyan Vasudevan , Yiqing Lin , Jin Xu , Andrea Trementozzi , Ivan Nestorov
IPC: A61K9/50 , A61K31/225 , A61K9/48
Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
-
公开(公告)号：US20200062705A1
公开(公告)日：2020-02-27
申请号：US16610817
申请日：2018-05-18
Applicant: Biogen MA Inc.
Inventor： Nishanth Gopinathan , Erwin Irdam , William Kiesman , Daw-long A. Kwok , Yiqing Lin , Frederick Osei-Yeboah , Matthew Peterson , Kenny Tran , Kalyan Vasudevan
IPC: C07D207/16
Abstract: The present invention is directed to novel crystalline forms of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide hydrochloride, to the use of said crystalline forms in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said crystalline forms and processes for their preparation.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.015 seconds)
